Completed
Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia
NCT00345410
- Conditions
- Body Weight, Dyslipidemia, Dyslipidemias, +9 more
- Locations
-
- Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States